Abstract：
BACKGROUND: Paracoccidioidomycosis (PCM) is the leading cause of death among systemic mycoses in Brazil. On the other hand, oral squamous cell carcinoma (OSCC) is the most prevalent malignant neoplasm of the mouth. Both lesions rarely affect the tongue dorsum and may share similar clinical characteristics. This study aimed to retrieve cases of single oral ulcers diagnosed as PCM or OSCC.
METHODS: A cross-sectional retrospective study was conducted. All patients who had a single ulcer on dorsum of the tongue and confirmed diagnosis of PCM or OSCC were evaluated.
RESULTS: A total of 9 patients (5 women and 4 men) were evaluated, 5 patients had OSCCs (mean age = 69,8 years old), and 4 patients PCM (mean age = 51 years old). Most of the lesions were infiltrated and indurated in the palpation exam. Duration ranged from 1 to 12 months (mean time of 5.2 months and 4.7 months for OSCC and PCM, respectively). OSCC was the main clinical diagnosis hypothesis.
CONCLUSIONS: Although uncommon, PCM and OSCC should be considered as a differential diagnosis hypothesis in infiltrated ulcers on the tongue dorsum. Incisional biopsy is mandatory to confirm the diagnosis and indicate the appropriate treatment.
METHODS: A cross-sectional retrospective study was conducted. All patients who had a single ulcer on dorsum of the tongue and confirmed diagnosis of PCM or OSCC were evaluated.
RESULTS: A total of 9 patients (5 women and 4 men) were evaluated, 5 patients had OSCCs (mean age = 69,8 years old), and 4 patients PCM (mean age = 51 years old). Most of the lesions were infiltrated and indurated in the palpation exam. Duration ranged from 1 to 12 months (mean time of 5.2 months and 4.7 months for OSCC and PCM, respectively). OSCC was the main clinical diagnosis hypothesis.
CONCLUSIONS: Although uncommon, PCM and OSCC should be considered as a differential diagnosis hypothesis in infiltrated ulcers on the tongue dorsum. Incisional biopsy is mandatory to confirm the diagnosis and indicate the appropriate treatment.
摘要：
背景：牙源性肿瘤发生的启动通常涉及MAP激酶途径的激活，具有关键作用的BRAFV600E突变。这项研究旨在调查在四个拉丁美洲中心诊断的成釉细胞瘤中BRAFV600E免疫表达的频率，并将这一发现与所分析病例的组织学类型和亚型相关联。
方法：使用抗BRAFV600E抗体对总共86个成釉细胞瘤样本进行免疫组织化学检查。分析每例的组织病理学特征。
结果：65/86例（75.6％）检测到抗BRAFV600E抗体阳性。BRAFV600E在38/56例（67.9％）常规成釉细胞瘤和27/30例（90.0％）单囊性成釉细胞瘤中呈阳性。当比较单囊性成釉细胞瘤与常规成釉细胞瘤时，观察到BRAFV600E阳性的统计学显着差异（p=0.03）。当比较组织学变异时，观察到BRAFV600E阳性无统计学差异，常规成釉细胞瘤和单囊性成釉细胞瘤。
结论：这项研究强调了拉丁美洲成釉细胞瘤中BRAFV600E免疫反应性的高频率。BRAFV600E免疫表达的普遍性可能表明利用BRAF靶向治疗具有该突变的成釉细胞瘤的可行性。
方法：使用抗BRAFV600E抗体对总共86个成釉细胞瘤样本进行免疫组织化学检查。分析每例的组织病理学特征。
结果：65/86例（75.6％）检测到抗BRAFV600E抗体阳性。BRAFV600E在38/56例（67.9％）常规成釉细胞瘤和27/30例（90.0％）单囊性成釉细胞瘤中呈阳性。当比较单囊性成釉细胞瘤与常规成釉细胞瘤时，观察到BRAFV600E阳性的统计学显着差异（p=0.03）。当比较组织学变异时，观察到BRAFV600E阳性无统计学差异，常规成釉细胞瘤和单囊性成釉细胞瘤。
结论：这项研究强调了拉丁美洲成釉细胞瘤中BRAFV600E免疫反应性的高频率。BRAFV600E免疫表达的普遍性可能表明利用BRAF靶向治疗具有该突变的成釉细胞瘤的可行性。
